17 patents
Utility
Multiplex Gene Edited Cells for CD70-DIRECTED Cancer Immunotherapy
7 Dec 23
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy.
James Barnaby Trager, Ivan Chan, Chao Guo, Luxuan Guo Buren, Alexandra Leida Liana Lazetic, Mary-Lee Dequéant, Hanspeter Waldner, Changan Guo, Chandirasegaran Massilamany, Ming-Hong Xie, Elizabeth N. Koch, Jacob Usadi, Parin Sripakdeevong
Filed: 6 Mar 23
Utility
Bcma-directed Cellular Immunotherapy Compositions and Methods
26 Jan 23
Provided for herein in several embodiments are immune cell-based compositions comprising BCMA-directed chimeric antigen receptors (CAR).
Kanya Lakshmi Rajangam, James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Alexandra Leida Liana Lazetic
Filed: 11 Jan 21
Utility
Truncated NKG2D Chimeric Receptors and Uses Thereof In Natural Killer Cell Immunotherapy
5 Jan 23
Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease.
Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
Filed: 10 May 22
Utility
Methods and Compositions for Enhanced Expansion and Cytotoxicity of Natural Killer Cells
29 Dec 22
Several embodiments disclosed herein relate to methods and compositions for enhanced expansion of NK cells in culture.
James Barnaby TRAGER, Alexandra Leida Liana LAZETIC, Ivan CHAN, Anmol VOHRA
Filed: 29 Jul 20
Utility
CD19-DIRECTED Chimeric Antigen Receptors and Uses Thereof In Immunotherapy
28 Jul 22
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors.
James Barnaby TRAGER, Luxuan Guo BUREN, Chao GUO, Mira TOHMÉ, Ivan CHAN, Alexandra Leida Liana LAZETIC
Filed: 7 Jan 22
Utility
Combinations of Engineered Natural Killer Cells and Engineered T Cells for Immunotherapy
28 Jul 22
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors and/or genetically modified to enhance one or more aspects of the efficacy of the immune cells in cellular immunotherapy.
James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Guangnan Li, Daofeng Liu, Ivan Chan
Filed: 2 Jun 20
Utility
Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
21 Jun 22
Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease.
Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
Filed: 27 Mar 18
Utility
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
22 Feb 22
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors.
James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
Filed: 4 Nov 20
Utility
Methods for the Simultaneous Expansion of Multiple Immune Cell Types, Related Compositions and Uses of Same In Cancer Immunotherapy
17 Feb 22
Several embodiments disclosed herein relate to methods and processes for the co-expansion of multiple types of immune cells, in order to generate a mixed cell population.
Daofeng LIU, Guangnan LI, James B. TRAGER
Filed: 22 Nov 19
Utility
Genetically Modified Natural Killer Cells for CD70-DIRECTED Cancer Immunotherapy
6 Jan 22
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy.
James Barnaby Trager, Alexandra Leida Liana Lazetic, Ivan Chan, Chao Guo, Katherine Jamboretz
Filed: 10 Jun 21
Utility
Natural Killer Cell Compositions and Immunotherapy Methods for Treating Tumors
4 Nov 21
Several embodiments disclosed herein relate to the treatment of a tumor using immunotherapy.
James Barnaby TRAGER, Angela Jean SHEN
Filed: 11 Sep 19
Utility
Cancer immunotherapy using CD19-directed chimeric antigen receptors
26 Oct 21
Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy.
James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
Filed: 4 Nov 20
Utility
Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
12 Oct 21
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors.
James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
Filed: 4 Nov 20
Utility
CD19-DIRECTED Chimeric Antigen Receptors and Uses Thereof In Immunotherapy
11 Mar 21
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors.
James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
Filed: 4 Nov 20
Utility
Immune Cells Engineered to Express CD19-DIRECTED Chimeric Antigen Receptors and Uses Thereof In Immunotherapy
11 Mar 21
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors.
James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
Filed: 4 Nov 20
Utility
Cancer Immunotherapy Using CD19-DIRECTED Chimeric Antigen Receptors
4 Mar 21
Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy.
James Barnaby Trager, Luxuan Guo Buren, Chao Guo, Mira Tohmé, Ivan Chan, Alexandra Leida Liana Lazetic
Filed: 4 Nov 20
Utility
Truncated NKG2D Chimeric Receptors And Uses Thereof In Natural Killer Cell Immunotherapy
29 Apr 20
Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease.
Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
Filed: 26 Mar 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first